Analysts Anticipate Evoke Pharma Inc (EVOK) to Announce -$0.22 EPS
Equities analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will announce earnings of ($0.22) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Evoke Pharma’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.18). Evoke Pharma posted earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The firm is scheduled to announce its next earnings results on Wednesday, March 21st.
On average, analysts expect that Evoke Pharma will report full-year earnings of ($1.00) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.96). For the next fiscal year, analysts forecast that the business will report earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). During the same period last year, the company earned ($0.29) EPS.
Evoke Pharma (EVOK) opened at $2.31 on Tuesday. The company has a market cap of $35.60, a PE ratio of -2.26 and a beta of 1.09. Evoke Pharma has a fifty-two week low of $1.87 and a fifty-two week high of $4.55.
An institutional investor recently raised its position in Evoke Pharma stock. Sphera Funds Management LTD. raised its position in shares of Evoke Pharma Inc (NASDAQ:EVOK) by 14.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 571,022 shares of the specialty pharmaceutical company’s stock after purchasing an additional 71,022 shares during the quarter. Sphera Funds Management LTD. owned approximately 3.71% of Evoke Pharma worth $1,907,000 at the end of the most recent quarter. 13.64% of the stock is currently owned by institutional investors and hedge funds.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.